Disease · MONDO_0004985

bipolar disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bipolar disorder. Diseases, record MONDO_0004985. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004985

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bipolar disorder; Open Targets
Open Targets ID: MONDO_0004985; Open Targets
Other names: Affective Bipolar Psychosis, Affective Psychosis, Bipolar, BIPOLAR DIS, BIPOLAR DISORDER NOS, Bipolar Affective Psychosis, Bipolar Depression, Bipolar Disorders, Bipolar affective disorder, Bipolar affective disorder , current episode mixed (disorder), Bipolar affective disorder, current episode depression (disorder), Bipolar affective disorder, manic, unspecified degree, Bipolar affective disorder, mixed, unspecified degree, Bipolar disorder (disorder), Bipolar disorder, unspecified, Depression, Bipolar, Depressive-manic psych., Disorder, Bipolar, Disorder, Manic, MANIC DEPRESSIVE ILLNESS, MANIC DIS, MDI - Manic-depressive illness, Mania, Manias, Manic Bipolar Affective disorder, Manic Depressive Psychosis, Manic Depressive disorder, Manic Disorder, Manic Disorders, Manic State, Manic States, Manic bipolar I disorder, Manic bipolar I disorder (disorder), Manic-Depressive Psychoses, Manic-depressive syndrome NOS, Psychoses, Bipolar Affective, Psychoses, Manic Depressive, Psychosis, Bipolar Affective, Psychosis, Manic Depressive, State, Manic, States, Manic, Unspecified bipolar affective disorder, Unspecified bipolar affective disorder (disorder), Unspecified bipolar affective disorder, NOS, Unspecified bipolar affective disorder, NOS (disorder), Unspecified bipolar affective disorder, unspecified, Unspecified bipolar affective disorder, unspecified (disorder), [X]Bipolar affective disorder, unspecified, [X]Bipolar affective disorder, unspecified (disorder), bipolar disease, bipolar disorder manic phase, major affective disorder, manic-depression, mixed bipolar I disorder (disorder), mixed bipolar affective disorder (disorder), mixed bipolar affective disorder, NOS (disorder), mixed bipolar disorder; Open Targets
Disease Ontology: DOID:3312; Disease Ontology
MeSH: D001714; MeSH
NCI Thesaurus: C34423; NCI Thesaurus
Highest stage of its drugs: Approval, for 23 of its 173 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs173

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed, EMA Human Drugs, FDA and PMDA	69	37	37	Drugs and targets
LITHIUM CARBONATE	CHEMBL1200826	Small molecule	Approval	DailyMed and TTD	79	33	16	Drugs and targets
DIVALPROEX SODIUM	CHEMBL2105613	Small molecule	Approval	DailyMed	120	27	24	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Approval	DailyMed and TTD	120	25	25	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Approval	DailyMed and EMA Human Drugs	129	22	21	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Approval	DailyMed	146	21	21	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Approval	DailyMed	20	19	16	Drugs and targets
QUETIAPINE FUMARATE	CHEMBL3188993	Small molecule	Approval	DailyMed and PMDA	124	16	16	Drugs and targets
ASENAPINE MALEATE	CHEMBL3544974	Small molecule	Approval	DailyMed	11	8	8	Drugs and targets
CARIPRAZINE	CHEMBL2028019	Small molecule	Approval	TTD	9	8	8	Drugs and targets

1 to 10 of 173

See all 173 drugs

Targets235

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	29	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	22	Serotonin (5-HT) receptor antagonist; Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	15	Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	10	Serotonin (5-HT) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	10	Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
DRD3	D(3) dopamine receptor	9	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor modulator; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
SCN2A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel protein type II alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel protein type III alpha subunit blocker	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN9A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker	Approval	https://conductscience.org/library/genes/6335	Drugs and targets
SCN10A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets

1 to 10 of 235

See all 235 targets

Trials375

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 19 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02775864	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia		81,921	2019-06-07	Schizophrenia, Schizoaffective Disorder	BENZODIAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT01358357	Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex	Phase 3	965	2016-07-26	Bipolar I Disorder	LURASIDONE	Its record names the disease	ClinicalTrials.gov
NCT01914393	Pediatric Open-Label Extension Study	Phase 3	702	2019-12-19	Schizophrenia, Autism, Bipolar Depression	LURASIDONE	Its record names the disease	ClinicalTrials.gov
NCT01396447	Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression	Phase 2	584	2018-05-01	Depression, Bipolar	CARIPRAZINE	Its record names the disease	ClinicalTrials.gov
NCT00141271	A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression	Phase 3	536	2009-03-24	Bipolar Disorder	ZIPRASIDONE	Its record names the disease	ClinicalTrials.gov
NCT02600507	Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression	Phase 3	529	2023-05-17	Bipolar Depression	LITHIUM, LUMATEPERONE, VALPROIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00510146	Olanzapine Treatment of Patients With Bipolar I Disorder	Phase 3	514	2011-05-26	Depression, Bipolar	OLANZAPINE	Its record names the disease	ClinicalTrials.gov
NCT02670538	Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder	Phase 3	493	2019-02-05	Bipolar Disorder, Depression	CARIPRAZINE	Its record names the disease	ClinicalTrials.gov
NCT02670551	Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression	Phase 3	488	2019-01-30	Bipolar Disorder, Depression	CARIPRAZINE	Its record names the disease	ClinicalTrials.gov
NCT04285515	Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder	Phase 3	488	2025-03-19	Bipolar Depression, Major Depressive Disorder	LUMATEPERONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 375

See all 375 trials

Comparisons in its trials135

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lumateperone 42mg vs Placebo: deaths from any cause	0 of 240	0 of 241	481	NCT04285515	Trial comparisons
Lumateperone 42mg vs Placebo: serious adverse events	0 of 240	1 of 241	481	NCT04285515	Trial comparisons
Iloperidone vs Placebo: deaths from any cause	0 of 206	0 of 208	414	NCT04819776	Trial comparisons
Iloperidone vs Placebo: serious adverse events	4 of 206	1 of 208	414	NCT04819776	Trial comparisons
Lumateperone vs Placebo: deaths from any cause	0 of 188	0 of 189	377	NCT03249376	Trial comparisons
Lumateperone vs Placebo: serious adverse events	1 of 188	0 of 189	377	NCT03249376	Trial comparisons
Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: Response Rate (Number of Patients With Clinically Response)	139 of 187	153 of 189	376	NCT00672490	Trial comparisons
Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: Remission Rate (Number of Patients With Clinically Significant Remission)	117 of 187	123 of 189	376	NCT00672490	Trial comparisons
Quetiapine Fumarate Used as Mono-Therapy vs Quetiapine Fumarate Used as Adjunct Therapy: serious adverse events	0 of 187	1 of 189	376	NCT00672490	Trial comparisons
Lithium+Quetiapine XR vs Placebo+Quetiapine XR: serious adverse events	4 of 173	8 of 183	356	NCT00931723	Trial comparisons

1 to 10 of 135

See all 135 comparisons in its trials

Papers from its trials323

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36579458	RESULT	1	PubMed
34149476	RESULT	1	PubMed
33688834	RESULT	1	PubMed
32785636	RESULT	1	PubMed
32637725	RESULT	1	PubMed
31744781	RESULT	1	PubMed
31651956	RESULT	1	PubMed
31237566	RESULT	1	PubMed
30986735	RESULT	1	PubMed
29920885	RESULT	1	PubMed

1 to 10 of 323

See all 323 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004985

GET https://conductscience.org/api/diseases/v1/MONDO_0004985/drugs?page=2

API reference For AI assistants